Meta’s AI Promise, Microsoft’s Disappointing Beat & Why Google Should Spin Youtube | Prof G Markets

Market Challenges

Eli Lilly faces significant market challenges, primarily due to supply chain issues and competitive pressures. Ed Elson highlights that while demand for Eli Lilly's GLP1 drugs like Zepbound and Mounjaro remains strong, supply constraints have hindered sales. However, Scott Galloway suggests that compounded GLP1 producers might be impacting demand by offering cheaper alternatives 1.

I wonder if it's some of the new guys or these compounded GLP1 producers maybe slowed their growth.

Ed Elson also points out a potential brand awareness issue, as competitors like Ozempic and Wegovy dominate public discourse, overshadowing Eli Lilly's products 2.

   

Competitive Landscape

The competitive landscape in the pharmaceutical industry is evolving, with new entrants challenging established players like Eli Lilly. Ed Elson and Scott Galloway discuss how companies like XAI are attempting to differentiate themselves by owning their entire supply chain, unlike others who rely on partnerships 3.

XAI has decided we're just going to own all of it ourselves.

This strategy, while ambitious, raises questions about whether XAI can compete with giants like Anthropic, given its current market position and valuation challenges 3.